Abstract:Background Due to high prevalence of ATTR cardiomyopathy among patients referred for transcatheter aortic valve replacement (TAVR), routine screening using nuclear scintigraphy with bone-avid radiotracers has been recommended in this population. Real-world adoption of these recommendations, however, is variable and is incompletely characterized, especially at programs in non-North American or European countries. Accordingly, we aimed to describe the utilization of Tc-99m pyrophosphate (PYP) scintigraphy in patients undergoing TAVR at a tertiary referral center in the Middle East. Methods Consecutive patients referred for TAVR (8/2015 to 12/2022) were retrospectively identified. Baseline clinical, echocardiographic, and imaging characteristics were ascertained using electronic health records. PYP imaging utilization was determined in the overall cohort, in a subgroup of male patients ≥65 years, and a subset enriched with echocardiographic features suggestive of cardiac amyloidosis (ventricular septal thickness ≥12 mm and mitral annular S` velocity ≤ 6 cm/s). Results A total of 266 patients underwent TAVR (75.6 ± 8.4 years, 56% men, 14.7% low-flow, low-gradient severe AS). Only 4.1% (11/266) patients underwent pre-TAVR PYP imaging, compared with 6.5% (9/138) male patients ≥65 years of age. PYP utilization was only modestly higher in a risk-enriched subgroup, where 7.2% (5/69) of patients underwent pre-TAVR imaging. All PYP studies demonstrated either no or grade 1 uptake by visual assessment, while no studies were suggestive of ATTR cardiomyopathy (grade 2 or 3 uptake). Conclusion In this real-world experience from an emerging program in the Middle East, both test utilization and diagnostic yield of pre-TAVR PYP scintigraphy were low. This may highlight major deficiencies in physician awareness about the cooccurrence of cardiac amyloidosis and aortic stenosis. Moreover, the current findings underscore the need for improved selection criteria for ATTR cardiomyopathy screening pre-TAVR in order to improve resource utilization and streamline patient management, especially since available lifesaving therapies for patients with concurrent disease are expensive.

Low Utilization Of Nuclear Scintigraphy For Cardiac Amyloidosis Evaluation Among Patients With Aortic Stenosis Referred For Transcatheter Aortic Valve Replacement